Research Funding Information

Printer Friendly

Below is a list of frequently asked questions about the ABTA's brain tumor research funding program. If you have additional questions, please email


Where can I find a list of the research now supported by ABTA?
A listing by researcher name, institution, and location is available at in the Brain Tumor Research section of the website, under the Currently Funded ABTA Research tab.


What type of tumors are ABTA researchers studying?
About 75% of the studies we currently support focus on glioblastoma and malignant gliomas. However, we recognize that research into other tumor types require similar research support. ABTA solicits and accepts applications from researchers looking at all types of brain tumors – primary and metastatic, adult and pediatric.
ABTA is currently supporting research into glioblastoma, astrocytomas, malignant astrocytomas, gliomas, metastatic brain tumors, and pediatric brain tumors. We are also providing funding for quality of life and symptom management studies.


Does ABTA support research into pediatric brain tumors?
Yes. We are currently funding research into brain stem tumors, medulloblastoma, malignant gliomas, glioblastoma, new drugs for pediatric tumors, and biomarkers of childhood brain tumors.


What type of research does ABTA fund? 

ABTA’s research funding focuses on three areas:

  • Career development initiatives. We provide opportunities for new and early career scientists wishing to enter or remain in brain tumor research.
  • Exploration of innovative research. We look for research with the potential to change the way brain tumors are diagnosed or treated.
  • Collaborative funding opportunities. We participate in initiatives by which we achieve greater impact through working with others.


Of each dollar donated to ABTA, how much is spent on ABTA programs?

Approximately 77 cents of each dollar is directed to ABTA’s programs, which includes research and patient services. ABTA program funding represents about 77% of the organization’s budget.


Does ABTA accept research-restricted donations?
Our Development team is available to speak to donors with specific funding interests and assist in identifying funding opportunities that match philanthropic interests.  Please call us at 866-659-1030 and ask for the Development Department.


Does ABTA have its own research facility? Does it conduct research on the premises?
ABTA does not conduct scientific research.  ABTA provides grants to researchers working in laboratories across the United States and Canada and from time to time will commission or collaborate on research into a specific area of interest to the organization and our constituents.


How are ABTA’s research awardees chosen?
ABTA’s awards are highly competitive and highly desirable. We use an application-based process to screen requests for funding and select studies with the greatest potential impact on the field. Applications are reviewed and scored based on specific, pre-defined criteria by our Scientific Advisory Council and Review Panels. The applications are ranked in accordance with our funding priorities, then reviewed by a research committee consisting of professionals and patient advocates. Applications with the greatest potential to help ABTA achieve its mission are then presented to the ABTA Board of Directors for final funding approval.


How do I meet ABTA’s researchers?

Each year, ABTA research grant awardees whose funding periods are concluding are required to present their outcomes in poster format during our annual Patients & Family Conference. Patients, their families and guests are invited to participate in this unique opportunity to meet the researchers, discuss their studies, and learn how ABTA’s support impacted their research. The 2014 annual meeting was held July 25-26. The outcomes of those projects are posted in the Research section of the ABTA web site.

The date of the 2015 meeting will be posted on the ABTA web site once available.


Who can address research questions not included in this FAQ?
Please direct e-mail inquiries to